Regeneron Pharmaceuticals (REGN) FCF Payout Ratio (2025 - 2026)
Regeneron Pharmaceuticals' quarterly FCF Payout Ratio came in at 0.12 in Q1 2026, little changed year-on-year from 0.11 in Q1 2025, and up 14.67% quarter-over-quarter from 0.1 in Q4 2025.
Regeneron Pharmaceuticals has reported FCF Payout Ratio for 2 years, with the latest figure at 0.12 in Q1 2026.
- For the quarter ending Q1 2026, FCF Payout Ratio changed 0.27% year-over-year to 0.12; the trailing twelve-month figure through Mar 2026 stood at 0.09 (up 200.93% YoY), and the FY2025 full-year result was 0.09, changed N/A from the prior year.
- FCF Payout Ratio for Q1 2026 stood at 0.12, up from 0.1 in the prior quarter.
- The five-year high for FCF Payout Ratio was 0.12 in Q1 2026, with the low at 0.08 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.12 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.12 |
| Dec 31, 2025 | 0.10 |
| Sep 30, 2025 | 0.08 |
| Jun 30, 2025 | 0.08 |
| Mar 31, 2025 | 0.11 |